Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Foghorn Therapeutics Inc. - Common Stock (NQ:FHTX)

5.430 -0.250 (-4.40%)
Streaming Delayed Price Updated: 12:41 PM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 36,869
Open 5.640
Bid (Size) 5.430 (200)
Ask (Size) 5.470 (500)
Prev. Close 5.680
Today's Range 5.400 - 5.660
52wk Range 2.945 - 6.950
Shares Outstanding 36,936,886
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
From Foghorn Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+4.6%
+4.6%
1 Month
+5.2%
+5.2%
3 Month
+22.9%
+22.9%
6 Month
+15.3%
+15.3%
1 Year
+2.6%
+2.6%

More News

Read More
News headline image
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
This Aardvark Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗
Via Benzinga
News headline image
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
This PayPal Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday ↗
Via Benzinga
News headline image
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
This Worthington Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
Via Benzinga

Frequently Asked Questions

Is Foghorn Therapeutics Inc. - Common Stock publicly traded?
Yes, Foghorn Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Foghorn Therapeutics Inc. - Common Stock trade on?
Foghorn Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Foghorn Therapeutics Inc. - Common Stock?
The ticker symbol for Foghorn Therapeutics Inc. - Common Stock is FHTX on the Nasdaq Stock Market
What is the current price of Foghorn Therapeutics Inc. - Common Stock?
The current price of Foghorn Therapeutics Inc. - Common Stock is 5.430
When was Foghorn Therapeutics Inc. - Common Stock last traded?
The last trade of Foghorn Therapeutics Inc. - Common Stock was at 02/09/26 12:41 PM ET
What is the market capitalization of Foghorn Therapeutics Inc. - Common Stock?
The market capitalization of Foghorn Therapeutics Inc. - Common Stock is 200.57M
How many shares of Foghorn Therapeutics Inc. - Common Stock are outstanding?
Foghorn Therapeutics Inc. - Common Stock has 201M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.